What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His scientific interests lie mostly in Melanoma, Cancer research, Pathology, Internal medicine and Oncology.
His Melanoma research focuses on Cutaneous melanoma in particular.
His work is dedicated to discovering how Cancer research, MAPK/ERK pathway are connected with Targeted therapy and other disciplines.
Richard A. Scolyer interconnects Nevus and Confidence interval in the investigation of issues within Pathology.
In his work, Radiation therapy is strongly intertwined with Carcinoma, which is a subfield of Oncology.
His Cancer study combines topics in areas such as Survival rate and V600E.
His most cited work include:
- Genomic Classification of Cutaneous Melanoma (1491 citations)
- Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. (793 citations)
- Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma (758 citations)
What are the main themes of his work throughout his whole career to date?
Richard A. Scolyer focuses on Melanoma, Pathology, Cancer research, Internal medicine and Oncology.
Particularly relevant to Cutaneous melanoma is his body of work in Melanoma.
His biological study spans a wide range of topics, including Dermatology and Nevus.
His Cancer research research is multidisciplinary, incorporating perspectives in Cell, Mutation, Immune system, Immunology and Neuroblastoma RAS viral oncogene homolog.
His Oncology research incorporates themes from Stage, Primary tumor, Disease and Hazard ratio.
His research integrates issues of Sentinel lymph node, Surgery and Sentinel node in his study of Biopsy.
He most often published in these fields:
- Melanoma (100.90%)
- Pathology (47.39%)
- Cancer research (38.20%)
What were the highlights of his more recent work (between 2017-2021)?
- Melanoma (100.90%)
- Internal medicine (38.11%)
- Cancer research (38.20%)
In recent papers he was focusing on the following fields of study:
Melanoma, Internal medicine, Cancer research, Oncology and Cutaneous melanoma are his primary areas of study.
His studies deal with areas such as Cancer, Metastasis, Immunotherapy, Breslow Thickness and Biopsy as well as Melanoma.
His Cancer research study also includes fields such as
- Immune system which intersects with area such as Cytokine,
- CD8 most often made with reference to T cell.
As part of the same scientific family, Richard A. Scolyer usually focuses on Oncology, concentrating on Lymph node and intersecting with Stage.
His research in Cutaneous melanoma intersects with topics in Mutation, Primary tumor, Proportional hazards model and Cohort.
Within one scientific family, he focuses on topics pertaining to Nivolumab under Ipilimumab, and may sometimes address concerns connected to Stage III melanoma.
Between 2017 and 2021, his most popular works were:
- Pan-cancer analysis of whole genomes (538 citations)
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study (352 citations)
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study (352 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
The scientist’s investigation covers issues in Melanoma, Internal medicine, Cancer research, Oncology and Cancer.
Cutaneous melanoma is the focus of his Melanoma research.
His Cutaneous melanoma research includes themes of Breslow Thickness, Nevus, Benign melanocytic nevus and Sentinel node.
His Cancer research research is multidisciplinary, incorporating elements of Cancer cell, Mutation, Gene mutation, Tumor-infiltrating lymphocytes and Chromatin.
His Oncology study integrates concerns from other disciplines, such as Discontinuation, Cytokine, Gene, Hazard ratio and Biomarker.
In his study, which falls under the umbrella issue of Cancer, Seer program is strongly linked to General surgery.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
